Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Inclusion Criteria: * Patients with a diagnosis of relapsed or refractory leukemia including, but not limited to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), T-cell prolymphocytic leukemia, biphenotypic acute leukemia, or blast-phase of chronic myeloid Leukemia (CML) will be allowed during the safety lead-in phase * For cohort A of the expansion phase: Patients with a diagnosis untreated adverse-risk AML (as defined by ELN \[European Leukemia Net Classification\] 2017) will be enrolled * For cohort B of the expansion phase: Patients with a diagnosis of relapsed or refractory AML will be enrolled * Bilirubin =\< 2 mg/dL * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN) * Creatinine =\< 1.5 x ULN * Cardiac ejection fraction of \> or = 45% within the past 3 months * Amylase and lipase =\< 1.5 x ULN * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * A negative urine pregnancy test is required within one week (7 days) for all women of childbearing potential prior to being registered on this trial * Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol Exclusion Criteria: * Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or ab…